Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment

Cancer

Volumn 118, Issue 21, 2012, Pages 5283-5292

  Quintás Cardama, Alfonso ^a   Qiu, Yi Hua ^a   Post, Sean M ^a   Zhang, Yiqun ^b   Creighton, Chad J ^b   Cortes, Jorge ^a   Kornblau, Steven M ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

blastic phase; chronic myeloid leukemia; chronic phase; protein expression; proteomics; reverse phase protein array; signature

Indexed keywords

APOPTOSIS INDUCING FACTOR; BINDING PROTEIN; CD34 ANTIGEN; GRB2 ASSOCIATED BINDING PROTEIN 2; HEAT SHOCK PROTEIN 90; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL 2; RETINOBLASTOMA PROTEIN; SINGLE STRANDED DNA BINDING PROTEIN; SINGLE STRANDED DNA BINDING PROTEIN 2 ALPHA; SMAD1 PROTEIN; TRIPARTITE MOTIF PROTEIN 24; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STEM CELL; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; CHRONICITY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVERSE PHASE PROTEIN ARRAY;

ANTIGENS, CD34; BLAST CRISIS; DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; NEOPLASTIC STEM CELLS; PROTEIN ARRAY ANALYSIS; TRANSCRIPTOME;

EID: 84867881861     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27568     Document Type: Article

References (27)

1. Quintas-Cardama A, Cortes J,. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009; 113: 1619-1630.
2. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
4. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010; 116: 3758-3765.
5. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349: 1423-1432.
6. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005; 11: 3425-3432.
7. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99: 3530-3539.
8. Hasford J, Ansari H, Pfirrmann M, Hehlmann R,. Analysis and validation of prognostic factors for CML. German CML Study Group. Bone Marrow Transplant. 1996; 17 (suppl 3): S49-S54.
9. Hehlmann R, Ansari H, Hasford J, et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German Chronic Myeloid Leukaemia (CML)-Study Group. Br J Haematol. 1997; 97: 76-85.
10. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006; 103: 2794-2799.
11. Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE, Radich JP,. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 2009; 114: 3292-3298.
12. Rogers S, Girolami M, Kolch W, et al. Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models. Bioinformatics. 2008; 24: 2894-2900.
13. Kornblau SM, Tibes R, Qiu YH, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009; 113: 154-164.
14. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR,. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res. 2010; 16: 1865-1874.
15. Heltemes-Harris LM, Willette MJ, Ramsey LB, et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med. 2011; 208: 1135-1149.
16. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006; 5: 2512-2521.
17. Saldanha AJ,. Java Treeview-extensible visualization of microarray data. Bioinformatics. 2004; 20: 3246-3248.
18. Holtz MS, Forman SJ, Bhatia R,. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia. 2005; 19: 1034-1041.
19. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R,. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002; 99: 3792-3800.
20. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002; 99: 319-325.
21. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107: 4532-4539.
22. Konig H, Holyoake TL, Bhatia R,. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood. 2008; 111: 2329-2338.
23. Peng C, Brain J, Hu Y, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood. 2007; 110: 678-685.
24. Peng C, Li D, Li S,. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle. 2007; 6: 2227-2231.
25. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007; 117: 2408-2421.
26. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011; 364: 205-214.
27. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol. 2011; 12: 852-861.